FY 2024/25: BRAIN Biotech AG benefits from successful monetisation of projects and strong corporate cost control
- Challenging sales environment, but strong corporate cost control
- Successful monetization of projects from the BRAINBioIncubator pipeline
- Group’s cash position remains solid at € 6.2 million
BRAIN Biotech AG, a leading provider of specialised enzymes and innovative biosolutions for industry, has released the BRAIN Biotech Group’s financial results for the 2024/25 financial year. During this period, consolidated revenue amounted to €49.6 million, reflecting a temporary adjustment from the previous year, primarily driven by challenging market conditions in pharma-related contract services within the BRAINBioIncubator segment.
Importantly, the Group demonstrated strong operational resilience and disciplined management. Successful cost containment initiatives ensured that adjusted EBITDA remained in line with the prior year, underlining the robustness of the Group’s business model. In addition, BRAIN Biotech maintained a solid cash position of €6.2 million while significantly reducing cash debt, further strengthening its financial foundation.
These results highlight the Group’s ability to navigate a demanding market environment while continuing to build a stable platform for future growth and innovation.
“BRAIN Biotech continues to move forward in a world full of volatility, uncertainty and complexity. The past financial year had its ups and downs.
